Safety and immunogenicity of combined diphtheria-tetanuspertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1384-1393

  Richie, E ^a   Punjabi, N H ^a   Harjanto, S J ^a   Wangsasaputral, F ^a   Sukandar, M ^a   Supriatman, M ^a   Simanjuntak, C H ^b   Que, J U ^c   Cryz Jr , S J ^c  

^a US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

^b NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^c Berna Biotech AG   (Switzerland)

Author keywords

Combined vaccines; H. influezae type b conjugate

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INDONESIA; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INDONESIA; INFANT; MALE; TETANUS TOXOID; TREATMENT OUTCOME; VACCINES, CONJUGATE;

EID: 0033577307     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00402-2     Document Type: Article

References (37)

1. Funkhouser A., Steinhoff M., Ward J. Haemophilus influenzae disease and immunization in developing countries. Rev Infect Dis. 13 (Suppl. 5):1991;42-54.
2. Bijlmer H.A., van Alphen L., Greenwood B.M., Brown J., Schneider G., Hughes A., Menon A., Zanen H.C., Valkenburg H.A. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in Gambia. West Africa J Inf Dis. 161:1990;1210-1215.
3. Moxon E.R., Wilson R. The role of Haemophilus influenzae in the pathogenesis of pneumonia. Rev Infect Dis. 13 (Suppl. 6):1991;S518-527.
4. Lehmann D. Epidemiology of acute respiratory tract infections, especially those due to Haemophilus influenzae, in Papua New Guinean children. J Infect Dis. 165 (Suppl. 1):1992;S20-25.
5. Makela P.H., Takala A.K., Peltola H., Eskola J. Epidemiology of invasive Haemophilus influenzae type b disease. J Infect Dis. 165 (Suppl. 1):1992;S2-6.
6. Chotpitayasunondh T. Bacterial meningitis in children: etiology and clinical features an 11-year review of 618 cases. Southeast Asian J Trop Med Publ Health. 25:1994;107-115.
7. Lohleka S. Acute bacterial meningitis in children. Thai J Pediatr. 30:1991;116-120.
8. Munson R.S., Kabeer M.H., Lenoir A.A., Granoff D.M. Epidemiology and prospects for prevention of disease due to Haemophilus influenzae in developing countries. Rev. Infect. Dis. 11 (Suppl.):1992;S588-597.
9. Bijlmer H.A. World-wide epidemiology of Haemophilus influenzae meningitis: industrialized versus non-industrialized countries. Vaccine. 9 (Suppl.):1991;5-10.
10. Peltola H., Kilpi T., Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet. 340:1992;592-594.
11. Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1987-1993. MMWR 1994;43:144-148.
12. Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1993-1994. MMWR 1995;44:545-550.
13. Shinefield H.R., Black S. Postlicensure surveillance for Haemo-philus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM 197 conjugate vaccine in a large defined United State population: a four-year eight-month follow up. Pediatr Infect Dis J. 14:1995;978-981.
14. Trollfors B., Taranger J., Lagergard T., Lind L., Sundh V., Zackrisson G., Lowe C.U., Blackwelder W., Robbins J.B. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med. 333:1995;1045-1050.
15. Storsaeter J., Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine. 10:1992;142-144.
16. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., Ciofo degli Atti M.L., Giammanco A., Panei P., Blackwelder W.C., Klein D.L., Wassilak S.G. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 334:1996;341-347.
17. Gustaffson L., Hallander H.O., Olin P., Reizenstein E., Strosaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 334:1996;349-355.
18. Schmitt H.J., Wirsing von Konig C.H., Neiss A.et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 275:1996;37-41.
19. Edwards K.M. Acellular pertussis vaccines: a solution to the pertussis problem? J Infect Dis. 168:1993;15-20.
20. Kaplan S.L., Lauer B.A., Ward M.A., Wiedermann B.L., Boyer K.M., Dukes C.M., Schaffer D.M., Paisley J., Mendelson R., Pedreira F., Fritzell B. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr. 124:1994;323-327.
21. Pichichero M.E., Latiolais T., Bernstein D.I., Hosbach P., Christian E., Vidor E., Meschievitz C., Daum R.S. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in 2-, 4- and 6-month-old infants. Pediatr Infect Dis J. 16:1997;863-870.
22. Eskola J., Ölander R.M., Hovi T., Litmanen L., Peltola S., Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet. 348:1996;1688-1692.
23. Shinefield H, Black S, Ray P et al. Safety of combined acellular pertussis DTaP-HbOC vaccine (Lederle-Praxis) in infants (Abstract G72). In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18-20, 1995. Washington, DC: American Society for Microbiology, 1995.
24. Chotpitayasunondh T., Panpitpat C., Thisyakorn U., Fürer E., Que J.U., Hasler T., Cryz S.J. Jr. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants. Southeast Asian J Trop Med Publ Health. 28:1997;91-98.
25. Panpitpat Ch, Thisyakorn U, Chotpitayasunondh T, Fürer E, Que JU, Hasler T, Cryz SJ, Jr. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b PRP-tetanus toxoid conjugate vaccine. WHO Bull., submitted for publication.
26. Mulholland E., Ahonkhai V., Greenwood A.M., Jonas L.C., Lukacs L.J., Mink C.M., Staub J.M., Todd J, Vella P.P., Greenwood B.M. Safety and immunogenicity of Haemophilus influenzae type b-Neisseria meningitidis Group B outer membrane complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J. 12:1993;632-637.
27. Lagos R., Kotloff K., Hoffenbach A., San Martin O., Abrego P., Ureta A.M., Pines E., Blondeau C., Bailleux F., Levine M.M. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J. 17:1998;294-304.
28. Foege W.H., Foster S.D. Multiple antigen vaccine strategies in developing countries. Am J Trop Med Hyg. 23:1974;685-689.
29. Krugman S. Hepatitis B vaccine. In: Plotkin SA, Mortimer EA, editors. Vaccines, ch. 21. Philadelphia: W.B. Saunders Company, 1988. p. 458-73.
30. Preblud SR, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA, editors. Vaccines, ch. 9. Philadelphia: W.B. Saunders Company, 1988. p. 182-222.
31. Suharyono, Simanuntak C., Witham N., Punjabi N., Heppner D.G., Losonsky G., Totosudirjo H., Rifai A.R., Clemens J., Lim Y.L., Burr D., Wasserman S.S., Kaper J., Sorenson K., Cryz S.J., Levine M.M. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 340:1992;689-694.
32. Robbins J.B., Parke J.C. Jr., Schneerson R., Whisnant J.K. Quantitative measurements of 'natural' immunization induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res. 7:1973;103-110.
33. Kayhty H., Peltola H., Karanko V., Makela P.H. The protective titer of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 147:1983;1100.
34. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of H. influenzae type b. J Infect Dis. 149:1984;1034-1035.
35. Weinberg G.A., Einhorn M.S., Lenoir A., Granoff P.D., Granoff D.M. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr. 111:1987;22-27.
36. Anderson P., Pichichero M., Edwards K., Porch C.R., Insel R. Priming and induction of Haemophilus influenzae type b capsular antibodies by Dpo20, an oligosaccharide-protein conjugate vaccine. J Pediatr. 111:1987;644-650.
37. Stein K.E. Thymus-independent and thymus-dependent responses to poly-saccharide antigens. J Infect Dis. 165:1992;S49-52.